Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 44 clinical trials
featured
A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis PASS – OBS13434

A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in patients with relapsing forms

alemtuzumab
multiple sclerosis
  • 724 views
  • 24 Nov, 2020
  • 1 location
featured
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease

Background: Peripheral blood stem cell transplantation procedures are used for people with sickle cell disease. Researchers want to improve the success and reduce the complications for these procedures. This might allow more people to have a transplant. Objective: To see if a new transplant regime is effective, safe and well …

red blood cell disorder
sickle cell disease
cell transplantation
stroke
  • 57 views
  • 22 Dec, 2020
  • 1 location
featured
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

  • 74 views
  • 25 Mar, 2021
  • 1 location
Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab Busulfan and TBI With Post-Transplant Cyclophosphamide

Background CGD causes infections and inflammation. The only cure currently is a bone marrow transplant. Most often a perfectly matched bone marrow donor is used. Researchers want to see if they can lower the risks of using a mismatched donor. Objectives To see if it is safe to use a …

graft versus host disease
alemtuzumab
sirolimus
bone marrow transplant
stem cell transplantation
  • 1 views
  • 15 Apr, 2021
  • 1 location
Allograft for Sickle Cell Disease and Thalassemia

ablation. If the graft is rejected, the patient will reconstitute autologous marrow function. We will use a combination of low dose irradiation, Alemtuzumab (Campath), and sirolimus. Peripheral

  • 28 views
  • 18 Feb, 2021
  • 1 location
RCT Comparing Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab in MS

immunomodulatory medication. The study has two treatment arms; arm A: HSCT (hematopoietic stem cell transplantation) and arm B: alemtuzumab, a registered immunomodulatory treatment of RRMS. A pre-planned 3-year

glatiramer acetate
alemtuzumab
interferon
natalizumab
teriflunomide
  • 35 views
  • 19 Feb, 2021
  • 9 locations
Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome

The investigators designed a compassionate basis phase II study for refractory/relapsed mycosis fungoides/Sezary syndrome consisting of alemtuzumab (Campath) for primary evaluation of

mycosis fungoides and sezary syndrome
sezary syndrome
campath
renal function test
mycosis
  • 54 views
  • 07 Nov, 2020
  • 1 location
Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure

RATIONALE: Immunosuppressive therapies, such as alemtuzumab and cyclosporine, may improve bone marrow function and increase blood cell counts. Giving alemtuzumab together with

anemia
bone marrow procedure
immunosuppressive agents
  • 44 views
  • 07 Nov, 2020
  • 1 location
Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP

antibody alemtuzumab in primary and relapsed T cell lymphoma. The investigators thus propose to investigate the value of adjuvant alemtuzumab in combination with dose dense CHOP-14 in patients

b-cell lymphoma
lymphoma
t-cell lymphoma
measurable disease
peripheral t-cell lymphoma
  • 10 views
  • 07 Nov, 2020
  • 1 location
Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation

monoclonal antibody Campath 1−H (Alemtuzumab) followed by long−term maintenance with the Calcineurin inhibitor Tacrolimus The recent development (and licensing in the UK) of an extended−release

alemtuzumab
induction therapy
immunosuppressive agents
tacrolimus
immunosuppression
  • 22 views
  • 07 Nov, 2020
  • 1 location